10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2015 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 24, 2016) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Revenues | |||
| Product sales | $ 32,151 | 24,474 | 10,804 |
| Royalty, contract and other revenues | 488 | 416 | 398 |
| Total revenues | 32,639 | 24,890 | 11,202 |
| Costs and Expenses | |||
| Cost of goods sold | 4,006 | 3,788 | 2,859 |
| Research and development expenses | 3,014 | 2,854 | 2,120 |
| Selling, general and administrative expenses | 3,426 | 2,983 | 1,699 |
| Total costs and expenses | 10,446 | 9,625 | 6,678 |
| Income from operations | 22,193 | 15,265 | 4,524 |
| Interest expense | (688) | (412) | (307) |
| Other income (expense), net | 154 | 3 | (9) |
| Income before provision for income taxes | 21,659 | 14,856 | 4,208 |
| Provision for income taxes | 3,553 | 2,797 | 1,151 |
| Net income | 18,106 | 12,059 | 3,057 |
| Net loss attributable to noncontrolling interest | (2) | (42) | (18) |
| Net income attributable to Gilead | 18,108 | 12,101 | 3,075 |
| Net income per share attributable to Gilead common stockholders - basic (in US$ per share) | 12.37 | 7.95 | 2.01 |
| Shares used in per share calculation - basic | 1,464 | 1,522 | 1,529 |
| Net income per share attributable to Gilead common stockholders - diluted (in US$ per share) | 11.91 | 7.35 | 1.81 |
| Shares used in per share calculation - diluted | 1,521 | 1,647 | 1,695 |
| Cash dividends declared per share (in US$ per share) | 1.29 | 0.00 | 0.00 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2015 | |||
Consolidated Statements of Comprehensive Income | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 24, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Net income | $ 18,106 | 12,059 | 3,057 |
| Other Comprehensive Income (Loss) | |||
| Net foreign currency translation gain (loss), net of tax | 9 | (9) | (44) |
| Available-for-sale Securities | |||
| Net unrealized gain (loss), net of tax impact of $(17), $0 and $4 | (29) | 1 | 5 |
| Reclassifications to net income, net of tax impact of $1, $0 and $0 | 1 | (1) | 0 |
| Net change | (28) | 0 | 5 |
| Cash Flow Hedges | |||
| Net unrealized gain (loss), net of tax impact of $21, $16 and $4 | 389 | 430 | (60) |
| Reclassification to net income, net of tax impact of $(19), $(4) and $(1) | (583) | 4 | 21 |
| Net change | (194) | 434 | (39) |
| Other comprehensive income (loss) | (213) | 425 | (78) |
| Comprehensive income | 17,893 | 12,484 | 2,979 |
| Comprehensive loss attributable to noncontrolling interest | (2) | (42) | (18) |
| Comprehensive income attributable to Gilead | 17,895 | 12,526 | 2,997 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
GILEAD SCIENCES, INC. | |||
Ticker: GILD Fiscal Year: 2015 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 24, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Operating Activities: | |||
| Net income | $ 18,106 | 12,059 | 3,057 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation expense | 161 | 125 | 103 |
| Amortization expense | 937 | 925 | 242 |
| Stock-based compensation expense | 382 | 360 | 252 |
| Excess tax benefits from stock-based compensation | (585) | (482) | (279) |
| Tax benefits from exercise and vesting of stock-based awards | 586 | 484 | 285 |
| Deferred income taxes | (393) | (236) | (98) |
| Other | (24) | 101 | 105 |
| Changes in operating assets and liabilities: | |||
| Accounts receivable, net | (1,397) | (2,578) | (315) |
| Inventories | (855) | 143 | (343) |
| Prepaid expenses and other assets | (90) | (371) | (170) |
| Accounts payable | 226 | (289) | (98) |
| Income taxes payable | 269 | 533 | 30 |
| Accrued liabilities | 2,632 | 2,013 | 312 |
| Deferred revenues | 374 | 31 | 22 |
| Net cash provided by operating activities | 20,329 | 12,818 | 3,105 |
| Investing Activities: | |||
| Purchases of marketable securities | (17,239) | (2,107) | (257) |
| Proceeds from sales of marketable securities | 4,792 | 807 | 494 |
| Proceeds from maturities of marketable securities | 719 | 52 | 78 |
| Other investments | 0 | (18) | 0 |
| Acquisitions, net of cash acquired | 0 | 0 | (379) |
| Capital expenditures | (747) | (557) | (190) |
| Net cash used in investing activities | (12,475) | (1,823) | (254) |
| Financing Activities: | |||
| Proceeds from debt financing, net of issuance costs | 9,902 | 7,932 | 0 |
| Proceeds from convertible note hedges | 784 | 2,543 | 2,774 |
| Purchases of convertible note hedges | 0 | (26) | 0 |
| Proceeds from issuances of common stock | 319 | 331 | 313 |
| Repurchases of common stock | (10,002) | (5,349) | (582) |
| Repayments of debt and other obligations | (997) | (4,779) | (4,440) |
| Payments to settle warrants | (3,865) | (4,093) | (1,040) |
| Excess tax benefits from stock-based compensation | 585 | 482 | 279 |
| Payment of contingent consideration | (3) | (101) | 0 |
| Payment of dividends | (1,874) | 0 | 0 |
| Contributions from noncontrolling interest | 188 | 35 | 152 |
| Net cash used in financing activities | (4,963) | (3,025) | (2,544) |
| Effect of exchange rate changes on cash and cash equivalents | (67) | (56) | 2 |
| Net change in cash and cash equivalents | 2,824 | 7,914 | 309 |
| Cash and cash equivalents at beginning of period | 10,027 | 2,113 | |
| Cash and cash equivalents at end of period | 12,851 | 10,027 | 2,113 |
| Supplemental disclosure of cash flow information: | |||
| Interest paid, net of amounts capitalized | 529 | 330 | 238 |
| Income taxes paid | 3,137 | 2,060 | 1,051 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
GILEAD SCIENCES, INC. | ||
Ticker: GILD Fiscal Year: 2015 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2015 10-K (Filed: Feb 24, 2016) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2015 | Dec 31, 2014 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $ 12,851 | 10,027 |
| Short-term marketable securities | 1,756 | 101 |
| Accounts receivable, net of allowances of $1,032 at December 31, 2015 and $356 at December 31, 2014 | 5,854 | 4,635 |
| Inventories | 1,955 | 1,386 |
| Deferred tax assets | 828 | 508 |
| Prepaid and other current assets | 1,519 | 1,057 |
| Total current assets | 24,763 | 17,714 |
| Noncurrent Assets | ||
| Property, plant and equipment, net | 2,276 | 1,674 |
| Long-term portion of prepaid royalties | 400 | 466 |
| Long-term deferred tax assets | 324 | 236 |
| Long-term marketable securities | 11,601 | 1,598 |
| Intangible assets, net | 10,247 | 11,073 |
| Goodwill | 1,172 | 1,172 |
| Other long-term assets | 1,056 | 731 |
| Total assets | 51,839 | 34,664 |
| Liabilities and Stockholders Equity | ||
| Current liabilities | ||
| Accounts payable | 1,178 | 955 |
| Accrued government and other rebates | 4,118 | 2,316 |
| Other accrued liabilities | 3,172 | 1,873 |
| Deferred revenues | 440 | 134 |
| Current portion of long-term debt and other obligations, net | 983 | 483 |
| Total current liabilities | 9,891 | 5,761 |
| Noncurrent Liabilities | ||
| Long-term debt, net | 21,195 | 11,921 |
| Long-term income taxes payable | 1,243 | 562 |
| Other long-term obligations | 395 | 586 |
| Commitments and contingencies (Note 11) | ||
| Temporary Equity | ||
| Equity component of currently redeemable convertible notes | 2 | 15 |
| Stockholders' Equity | ||
| Preferred stock, par value $0.001 per share; 5 shares authorized; none outstanding | 0 | 0 |
| Common stock, par value $0.001 per share; shares authorized of 5,600 at December 31, 2015 and December 31, 2014; shares issued and outstanding of 1,422 at December 31, 2015 and 1,499 at December 31, 2014 | 1 | 2 |
| Additional paid-in capital | 444 | 2,391 |
| Accumulated other comprehensive income | 88 | 301 |
| Retained earnings | 18,001 | 12,732 |
| Total Gilead stockholders equity | 18,534 | 15,426 |
| Noncontrolling interest | 579 | 393 |
| Total stockholders equity | 19,113 | 15,819 |
| Total liabilities and stockholders equity | 51,839 | 34,664 |
| External Links | |
| GILEAD SCIENCES, INC. (GILD) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |